Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...